Companies will work on preclinical development of remote-controlled microscale robots to deliver novel oncolytic viral immunotherapies in specific brain tumors LOS ANGELES and NEEDHAM, Mass., December 15, 2021 (GLOBE NEWSWIRE)…
Read More
First-in-class Bionaut™ treatment modality will use remote-controlled microscale robots to treat rare pediatric neurological disorder Company also appoints renowned expert in targeted therapeutics and former Kite CEO Aya Jakobovits, Ph.D.,…
The U.S. Food and Drug Administration (FDA) has granted Bionaut Labs orphan drug designation for BNL-101 for the local treatment of all malignant gliomas including diffuse intrinsic pontine glioma in…
In this segment from FOX 11’s Good Day LA, reporter Bob DeCastro visits Bionaut Labs and speaks with chief executive Michael Shpigelmacher about the potential life-saving applications of the technology...
Read More
L.A. Biz recently sat down with CEO Michael Shpigelmacher to discuss the official launch of the company and the technology behind Bionauts. Bionaut Labs has captured the imagination of the…
In this video, Bionaut Labs CEO Michael Shpigelmacher joins Krisztina ‘Z’ Holly from Good Growth Capital for a fireside chat as part of LA MedTech Week. Shpigelmacher discusses the development…
First-in-class Bionaut™ treatment modality uses remote-controlled microscale robots to deliver biologics, nucleic acids, or small molecule therapies locally to targeted brain disease areas $20M financing led by Khosla Ventures supports…